
## **Supplementary Table 1 | Demographics of evaluated patient samples.** Age, sex

- 2 (proportion of female patients), patient outcome (proportion of surviving patients), and
- 3 SARS-Cov-2 status of patient samples tested in this study.


Demographics	Age (yrs)	Sex (F/M)	Outcome (S/D)	SARS-CoV-2 (+/-)
Average	66.68	0.34	0.74	0.53
SD	16.86			
Sample n	490	490	490	489
Patient n	82	82	82	82

Supplementary Table 2 | Accuracy of SARS-CoV-2 rapid-ELISA assay. Positive predictive value (PPV) or negative predictive value (NPV) were calculated for the rapid-ELISA technique of samples 10+ days postinfection. Positivity was assigned to samples that exhibited anti-N and anti-RBD antibody production.


True (+)	False (+)	True (-)	False (-)
196	0	5	51 1
Total Samples		247	
PPV		99.5%	
NPV		100%	



Supplementary Figure 1 | Rapid-ELISA results of all days post-symptom onset vs. 7 8 days 11+. Mean antibody responses of all patient samples (All) were compared to mean 9 antibody responses occurring after ten days post-infection (10+). Anti-SARS-Cov-2 IgG 10 responses were not significantly different between all samples and samples ten days after 11 infection for all antigens. Both sample groups were significantly different than negative SARS-CoV-2 patients (-). Statistical analysis was assessed by one-way ANOVA followed 12 by Sidak's multiple comparison test. \*\*\*\* = p<0.0001 compared to negatives (-). n.s. = not 13 significant between All and 10+ groups. 14




Supplementary Figure 2 | Early antibody responses of SARS-CoV-2 patients do not differ based on patient outcome. Anti-SARS-CoV-2 lgG responses during the first ten days of infection were measure for patients surviving (S), or not surviving (D) SARS-Cov-2 infection. Both samples were significantly different than patients that did not have SARS-CoV-2 infection (-). Statistical analysis was assessed by one-way ANOVA followed by Sidak's multiple comparison test. \* = p<0.05 compared to negatives, \*\*\*\* = p<0.0001 compared to negatives (-). n.s. = not significant between S and D groups.






Supplementary Figure 3 | Anti-SARS-CoV-2 antibody response correlates directly
with age. IgG production to RBD (A), N (B), or S1 (C) or surviving SARS-CoV-2 positive
patients as correlated to their age in years. Correlation was assessed by calculating
Pearson correlation coefficients.



30

Supplementary Figure 4 | Cytokine response to SARS-CoV-2 infection. Concentration of (A) IL-6, (B) IL-8, (C) IP-10, (D) IL-18, (E) MIP-1 $\beta$ , (F) MCP-1, (G) SDF-1 $\alpha$ , (H) eotaxin, (I) IL-1 $\beta$ , (J) IL-2, (K) IL-4, (L) IL-5, (M) IL-12, (N) IL-13, (O) RANTES, (P) IFN- $\gamma$ , (Q) GM-CSF, (R) TNF- $\alpha$ , (S) GRO- $\alpha$ , and (T) MIP-1 $\alpha$  in patient plasma samples. -SARS-CoV\_2 negative patients, + = SARS-CoV-2 positive patients, S = SARS-CoV-2<sup>+</sup> patients that survived infection, D = SARS-CoV-2<sup>+</sup> patients that did not survive infection.


- 37 Statistical significance was assessed with a two-tailed Welch's t-test. \* = p<0.05, \*\* =
- *p*<0.01 \*\*\* = *p*<0.001, \*\*\*\* = *p*<0.0001, n.s. = not significant.



41 Supplementary Figure 5 | CXCL13 production by SARS-CoV-2 patients. CXCL13

42 production by SARS-CoV-2 production is compared to anti-RBD, anti-N, or anti-S IgG

- 43 quantity over the course of patient disease. Patient age, sex, and status (S = survived,
- 44 D = deceased) are represented left of the patient data.



Supplementary Figure 6 | N/RBD or N/S1 ratios are associated with disease severity. The anti-nucleocapsid AUC was divided by either the (A) anti-RBD AUC or (B) anti-S1 AUC of patient samples grouped by whether they survived (S) or did not survived (D) SARS-CoV-2 infection. Statistical significance was assessed with a two-tailed Welch's t-test. \*\* = p<0.01, \*\*\* = p<0.001.

